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For many cancer types, incidence rises rapidly with age as an
apparent power law, supporting the idea that cancer is caused by
a gradual accumulation of genetic mutations. Similarly, the in-
cidence of many infectious diseases strongly increases with age.
Here, combining data from immunology and epidemiology, we
show that many of these dramatic age-related increases in incidence
can be modeled based on immune system decline, rather than
mutation accumulation. In humans, the thymus atrophies from
infancy, resulting in an exponential decline in T cell production with
a half-life of ∼16 years, which we use as the basis for a minimal
mathematical model of disease incidence. Our model outperforms
the power lawmodel with the same number of fitting parameters in
describing cancer incidence data across a wide spectrum of different
cancers, and provides excellent fits to infectious disease data. This
framework provides mechanistic insight into cancer emergence, sug-
gesting that age-related decline in T cell output is a major risk factor.
cancer | infectious disease | T cell | thymus | driver mutations
T cells develop from hematopoietic stem cells as part of thelymphoid lineage and have the ability to detect foreign anti-
gens and neoantigens arising from cancer cells. In the thymus,
lymphoid progenitors commit to a specific T cell receptor and un-
dergo selection events that screen against self-reactivity. Cells that
pass these selection gates then leave the thymus, clonally expanding
to form the patrolling naive T cell pool (1). The vast majority of
vertebrates experience thymic involution (or atrophy) in which thy-
mic epithelial tissue is replaced with adipose tissue, resulting in de-
creasing T cell export from the thymus. In humans, this is thought to
begin as early as 1 y of age (2) (Fig. S1). The rate of thymic T cell
production is estimated to decline exponentially over time with a
half-life of ∼15.7 y (2–4), thereby following the function e−αt, with
α = 0.044 y−1. Declining production of new naive T cells is thought
to be a significant component of immunosenescence, the age-related
decline in immune system function. With the recent successes of T
cell–based immunotherapies (5), it is timely to assess how thymic
involution may affect cancer and infectious disease incidence.
It is clear from epidemiological data that incidence of in-
fectious disease and cancer increases dramatically with age, and,
specifically, that many cancer incidence curves follow an appar-
ent power law (6, 7). The simplest model to account for this
assumes that cancer initiation is the result of a gradual accu-
mulation of rare “driver” mutations in one single cell. Further-
more, the fitting of this power law model (PLM) can be used to
estimate the number of such mutations (6, 7). Exponential curves
(i.e., of the form eλt) have also been used to fit cancer incidence
data (8), resulting in worse fits than the PLM overall. Never-
theless, it is worth noting that exponential rates close to α =
0.044 y−1 can be seen to emerge from the incidence data (Fig.
S2), indicating the relevance of the thymic involution timescale.
While the PLM fits well, it does not account for changes in the
immune system with age. To better determine the processes
underlying carcinogenesis, we asked whether an alternative
model, based only on age-related changes in immune system
function, might partly or entirely explain cancer incidence.
Results
Immunological Model. We developed a mathematical model of
cancer incidence based on two assumptions: first, that potentially
cancerous cells arise with equal probability at any age, and,
second, that there exists an immune escape threshold (IET),
proportional to T cell production, above which immunogenic
cells can overwhelm the immune system and result in a clinically
detectable disease (Fig. 1 and Fig. S3). For the sake of generality,
as the model can also relate to age-related incidence of in-
fectious diseases, the immunogenic cells could be mutated so-
matic cells or a population of infectious pathogens. We do not
define the biological interaction between the T cell pool and the
nascent tumor/infection; however, the concept of declining im-
mune competence is consistent with several known mechanisms:
for instance, both T cell repertoire diversity and the proliferative
capacity of naive T cells decrease with age (9). Our model is thus
derived as follows: once immunogenic cells arise, the population
of such cells will change over time, leading to stochastic dynamics
in population size, clonal diversity, and potentially other prop-
erties. The simplest way to capture these dynamics is through a
birth–death process, and to a first approximation this can be
modeled as a biased random walk (10). Fig. 1 provides a schematic
view of the model dynamics in terms of population size. If the
random walk exceeds the IET, the immune system will no longer
be able to respond effectively and immune escape occurs.
If the random walk for the immunogenic cells is unbiased (e.g.,
for the random walk describing population size, if cell division
and cell death are equally likely), then the probability for an im-
munogenic cell population to reach a threshold K is given by 1/K
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(Methods). This gives a first-approximation prediction that the risk
of immune escape, which we denote by R, rises exponentially with
age at the same rate that T cell production declines. This defines a
model for disease incidence with one fitting parameter, that being
an overall prefactor (Table 1). If the random walk is biased (e.g., if
the rates of cell division and cell death are not equal), a similar
calculation produces a more general prediction for incidence with
one additional parameter (Table 1). We will refer to these one-
and two-parameter model predictions as, respectively, immune
model I (IM-I) and immune model II (IM-II). The additional
fitting parameter of IM-II can be interpreted as a “pivot age,”
which marks a transition from very low to relatively much higher
risk (Methods). We stress that α is not a fitting parameter, but the
empirically derived rate from thymus involution, given by 0.044 y−1,
which we use for all of our analysis.
Infectious Disease Incidence. For most infectious diseases, the in-
crease in risk with age is believed to be due to changes in the
immune system and therefore provides a good first test for our
model. The assumption that the immunogenic cells arise with
equal probability at any age amounts to assuming constant ex-
posure across age groups. We found that six of the seven bac-
terial infections monitored by the Active Bacterial Core (ABC)
surveillance program (Data Sources) fit IM-II well (R2 > 0.9),
with better fitting for those incidence curves underpinned by
higher incidence and larger population sizes and hence associ-
ated with a smaller relative uncertainty [i.e., smaller confidence
intervals (CIs)]. Turning to viral diseases, the incidence of West
Nile virus (WNV) disease is particularly well fit by IM-II (and
indeed IM-I). However, influenza A is not fit well, instead rising
exponentially at a faster rate (Fig. 2). Prevalence of tuberculosis
infection in Cambodia also fits the model well (Fig. S4). Indeed,
even IM-I fits these infectious diseases very well, which confirms
the importance of the thymic involution timescale. This provides
confidence in applying our approach further.
Cancer Incidence.We next tested our model against cancer incidence
curves, across 101 cancer types under the ICDO3 WHO2008
classification (11). Fitting IM-II to the incidence curves, the
median R2 was found to be 0.956, with 57 cancer types fitting
very well (R2 > 0.95). Since IM-II has the same number of
fitting parameters as the widely used PLM of cancer incidence,
a direct comparison is possible. The PLM performs slightly
worse overall (R2 > 0.95 for 48 cancer types, median R2 = 0.947;
R2 and associated fitting measures for each cancer type can be
found in Dataset S1), with cancers whose incidence rises ex-
ponentially, such as chronic myeloid leukemia (CML) and brain
cancer, fitting IM-I and IM-II better than the PLM. Many
cancer types, including colon and gallbladder, fit both the PLM
and IM-II very well (Fig. 3). There are no examples of PLM
fitting well and notably better than IM-II. The ability of IM-II
to capture the power law behavior seen in cancer incidence curves is
an unexpected feature of the model and is discussed further in
SI Theory [where we show that IM-II exhibits an apparent power
law with power e/(e − 2) ∼ 3.78 in the age range of 33–82 y]. We
note that, of the top 10 best-fit cancers, the 9 carcinomas have pivot
ages tightly clustered from 56.3 to 60.5 y (Dataset S1), suggesting a
clinical significance of the mid- to late fifties as an age of particular
importance for screening and intervention. In contrast, the PLM by
definition is “scale-free” and thus has no associated age range of
particular importance from a clinical perspective.
From the form of the equation of IM-II we can see that, up to
a shift in age and an overall multiplicative factor, all incidence
curves should follow the same function (Methods and Fig. 3D).
This “universal scaling function” shows the range of behaviors
possible within the model. Indeed, the quality of data collapse of
incidence data onto the universal scaling function for IM-II is
excellent, giving strong support to our model and highlighting
those cancer types that fit the model particularly well. One such
cancer, CML, is characterized by a single translocation event
resulting in the formation of the Philadelphia chromosome (12).
This is a good candidate for the type of initiating event featured
in our model. Assuming this translocation event can happen at
Fig. 1. Declining T cell production leads to increasing disease incidence. Our model assumes that immunogenic cells arise with the same probability at any
age, and, after a period of being targeted, the population may overwhelm the immune system by crossing an immune escape threshold. This threshold is
assumed to be proportional to T cell production, which decreases with age. This provides a prediction for the possible forms of disease incidence curves.
Table 1. Summary of the mathematical forms of the immune models and the PLM
Model Predicted risk profiles Free parameters Brief description
Immune model I R=A  eαt A Risk doubles every 16 y
Immune model II R=A=ðee−αðt − τÞ −1Þ A, τ Risk profile shifts around a pivot age of τ years
Power law (multistep) model R=A  tγ A, γ Waiting time for γ + 1 rare events (6, 7)
The risk of contracting a disease, R, as a function of age, t, can be modeled by immunological models or the PLM. The model
parameter α is given by 0.044 y−1, while the free parameters are obtained by fitting the models to each disease and are available in
Dataset S1.
2 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1714478115 Palmer et al.
any age, on neglecting the IET one might expect that incidence
would be approximately constant. Instead, incidence doubles
every 16 y, mirroring the exponential decay of T cell production,
consistent with our model.
Examining which incidence curves fit poorly can give insight
into the underlying diseases (Fig. S11, R2 < 0.9 for 28 cancer
types with IM-II and 34 cancer types with PLM). For example,
breast and thyroid cancer both rise rapidly and then plateau from
middle age onward, possibly due to the significant hormonal
influences for these cancers. Many cancer types have a plateau or
even a dip in incidence around age 80. This cannot be explained
by either IM-II or the PLM, since both give strictly increasing
incidence with age. One can speculate that this decrease might
be explained by declining tissue turnover. If this were the case,
one would then expect cancer of the population of developing
T cells itself (T cell lymphoblastic leukemia) to have an approxi-
mately constant risk profile with age, due to an exact cancellation of
increasing risk from immunosenescence and decreasing risk from
reduced cell production. This behavior is indeed observed when
looking at adults above age 18 (Fig. S5). This finding supports the
idea that both immune decline and decreasing tissue turnover
contribute significantly to changes in cancer risk with age.
Our model has the potential to provide clinical insight into
differences between cancer types. For example, those cancer
types with a higher pivot age could be linked to tissues with a
higher IET (Methods). This would decrease the probability of
cancer initiation per se but would also imply that such cancers
are larger or more advanced at the point of immune escape.
From this, one would expect that pivot age should be inversely
correlated with survivability, which indeed we observe (r = −0.6;
value of P < 10−8; Fig. S7). To further test our model, we
compared groups for which there are measurable differences in
T cell production and disease incidence. While disease incidence
is known to increase in immune-compromised groups, compar-
ing males to females in the general population is more easily
quantifiable. There is a gender bias in quantities of T cell
receptor excision circle (TREC) DNA with age (4), which can be
used to infer differences in naive T cell production between
males and females. Interestingly, cancer is more common overall
in males than females by a factor of 1.33 (13). We calculate that
the TREC measurements from males and females have a similar
gender bias, with females having 1.46 ± 0.31 (mean ± SD) more
TREC DNA overall (4). As well as overall TREC counts, there is
a difference in the rate of decline, with male TRECs falling faster
(4). Consistently, the incidence data shows that 70 out of the
87 cancers with gender separation (i.e., observed in both genders)
rise more steeply in males (Methods). To illustrate this bias, we
constructed universal scaling functions for each gender (Fig. 3E and
Fig. S9D), each showing good data collapse. Interestingly, a similar
gender bias is found in the average mutation burden in cancer bi-
opsies, showing a steeper increase with age in males (14). WNV, the
only infectious disease in our dataset with gender separation, also
shows steeper increase in risk for males (value of P < 0.01).
For the majority of cancers, both the PLM and IM-II fit very
well. To investigate further, we constructed a combined power
law immunological model (PLIM), which includes rising risk with
age from accumulating mutations and from immune system de-
cline. This model has three fitting parameters, and is therefore
relatively weaker as a predictive model, but does contain as
submodels the PLM and IM-II (and hence IM-I). The model
predicts risk profiles of the following form:
R=
A
eBe−αt − 1
tγ ,
where A, B, and γ are fitting parameters (Methods). The param-
eter γ is once again interpreted as corresponding to γ + 1 driver
mutations, while the parameter B indicates how much immune
system decline contributes to rising risk with age. We found that
this model provides good fits along a line in parameter space
linking IM-II to the PLM (Fig. S8). For the cancers showing
exponential behavior (brain, CML, and soft tissue including
heart), the best fit is found very close to the IM-II (and indeed
IM-I) region of parameter space, whereas for the cancers show-
ing power law behavior, some cancers have their best fit close to
the PLM region of parameter space. For colon and rectum can-
cer, the best fit occurs in-between the two regions, with a value of
γ = 1.2 corresponding to 2.2 driver mutations. This estimate
matches the value of 2.3 driver mutations for colorectal cancer
found in ref. 15. Since the incidence curve fits a power law very
accurately with exponent γ = 4.6, the estimate of 2.3 driver mu-
tations suggests that the time dependence factorizes as R =
Raccumulation × Rimmune, where Raccumulation ∝ t1.3 and Rimmune ∝ t3.3.
It is noteworthy that the contribution of 3.3 to the net power law
exponent of 4.6 is close to the value 3.78, which follows from the
apparent power law behavior of IM-II, as discussed earlier. This
factorization would imply that immune decline contributes more
than accumulation of mutations to the increase in risk with age for
colorectal cancer.
Discussion
We have shown that there is a strong link between T cell pro-
duction and incidence of both infectious diseases and cancer.
Some disease incidence curves rise exponentially, inversely pro-
portional to T cell production (Fig. 3 and Fig. S8), while some
rise in a manner well-captured by our two-parameter model, IM-
II. This simple model, comprising (i) a threshold proportional to
T cell production and (ii) a biased random walk characterizing
the population dynamics of the immunogenic cells, can explain,
to a large extent, cancer and infectious disease incidence, in-
cluding gender differences. Further research is needed on the
precise form of the IET to understand how it interfaces with
declining T cell production in different diseases and individuals.
The immunological model provides a fresh perspective on car-
cinogenesis, strongly supporting the idea that cancer can be
caused by a single event in one cell that subsequently manages to
Fig. 2. Infectious disease incidence. Log-linear plots of incidence (per
100,000 person-years) by age group for all ABC bacterial infections, West
Nile virus (WNV) disease, and Influenza A, ordered from best fit to worst.
Bacterial and viral diseases are shaded yellow and green, respectively. The
two-parameter IM-II is in red, while the one-parameter IM-I is in orange.
Incidence often decreases initially from birth due to an underdeveloped
immune system in infants; therefore, models are fitted only to data points
for ages greater than 18 y. Error bars show 99% CIs for all diseases.
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beat the odds and evade the immune system through rare sto-
chastic fluctuations in population dynamics. This is in stark
contrast to the PLM, where the increase in risk with age arises
from the waiting time for multiple independent events. We also
predict that, for those animals that do not experience thymic
involution, for example, some species of shark (16), cancer risk
would not increase dramatically with age, and would thus be a
relatively rare cause of death.
Mutations do indeed accumulate with age (17, 18), and al-
though the premise of the PLM is logically and mathematically
sound, this model predicts that several rare independent driver
mutations are necessary for carcinogenesis. The fitted curves
from the PLM and IM-II often overlap and can explain equally
well many incidence curves. Further research is therefore nec-
essary to estimate the number of driver mutations via other lines
of inquiry. A recent paper (15) attempted to address this ques-
tion from a new direction, by comparing groups with different
mutation rates such as smokers and nonsmokers. Their analysis
suggests that lung and colon cancer are caused by approximately
n ∼ 2.3 driver mutations, rather than n ∼ 6.3 as would be inferred
from the PLM alone. Our combined PLIM also predicts approxi-
mately n ∼ 2.2 driver mutations for colon cancer, although good fits
(R2 > 0.95) are also found in other areas of parameter space.
Moreover, a correlation has been found between the risk of cancer
in a given organ and the total number of stem cell divisions esti-
mated for that organ (19). It has been noted that this correlation
A
B
D E
C
Fig. 3. Cancer incidence. Log-linear plots of incidence (per 100,000 person-years). Data taken from SEER (11). (A and B) Some cancer types rise exponentially
fitting IM-I (A), while some cancer types rise like power laws, although can still be fit by IM-II (B). Fitting curves for IM-II and PLM are shown in red and green,
respectively. (C) The top 20 best-fitting incidence curves as measured by Akaike Information Criterion (AIC) for IM-II. (D and E) Universal scaling functions for
all cancers with defined pivot ages (84 out of 101 cancer types) plotted in gray with the top 20 incidence curves highlighted. Data shown for both genders (D)
and gender-separated data (E), with dotted lines showing the model predictions for IM-I and IM-II. The gender-separated curves are fitted with higher in-
dependently determined values for α in males than females, reflecting the gender bias in T cell production (Methods). A purely exponential incidence curve
would correspond to a pivot age of negative infinity, and therefore, for the purposes of plotting, we set a minimum pivot age of −50 y. Models are fitted only
for ages greater than 18 y. Error bars show 95% CIs for all diseases.
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does not show a highly nonlinear relationship, which would be
expected from the mutation accumulation hypothesis (20). Indeed,
if we apply the PLM to this dataset (Dataset S2), we find that the
number of driver mutations is just n∼ 0.91 (SI Theory) consistent
with the assumptions underpinning the immunological model.
While IM-II has only two emergent fitting parameters, the un-
derlying random-walk model has three biological parameters,
resulting in an underdetermined system (Methods). To get estimates
for these biological parameters, such as the size of the IET, addi-
tional assumptions are required. Given that the estimated total
number of stem cell divisions provides a good predictor of cancer
risk (19), the rate of stem cell divisions can be assumed to be
proportional to the rate of cancer initiation attempts in the im-
munological model (SI Theory). From this, we can obtain values for
the model parameters of IM-II. We found that the size of the IET is
typically ∼106, which would imply that a population growing beyond
106 cancer cells would overwhelm the immune system and result in
immune escape (see Dataset S1 for values for each cancer). In
mouse experiments, primary inoculations with >106 cancer cells
rendered mice unable to control subsequent tumor inoculations
(21), providing a degree of qualitative and quantitative support for
our model assumptions. This effect is related to the phenomenon of
“T cell exhaustion,” which was initially defined as the clonal de-
letion of antigen-specific T cells due to chronic stimulation (22), and
is now understood to involve not only activation-induced deletion
but also changes in T cell phenotype and functionality (5). Thera-
pies targeting T cell exhaustion have already been widely successful
in cancer and infectious disease therapy in the form of immune
checkpoint blockades such as PD-1 and CTLA-4 inhibitors (5). Our
model provides a theoretical framework for such treatments and
predicts that treatment efficacy could be enhanced if new naive
T cell production were also increased. Additionally, evidence for a
causative link between thymic activity and cancer risk has been
found in mouse models, as thymectomized mice develop signifi-
cantly more tumors (23, 24) and thymus grafts on nude mice can
induce cancer remission (25, 26).
Our view supports the idea that as little as one single genomic
aberration could be at the root of tumorigenesis. This event
could be the emergence of a potent driver mutation, for example,
a growth-inducing chromosomal translocation. Interestingly, it
has been pointed out that a relatively small number of oncogenes
have been confirmed across multiple biological experiments and
all of these genes control cellular growth (27). Moreover, kar-
yotypic analysis indicates that chromosomal rearrangements are
encountered in most cancers in a way that is generally unique to
the specific cancer under consideration (28). This led some to
suggest that such changes are causative to cancer (29). Our
analysis indicates that a single event (e.g., the emergence of a key
mutation) could be enough to generate a malignancy that is able
to evolve into a clinically manifest cancer if it escapes immune
control. The immunological model also identifies a potential
smoking gun in cancer risk in the form of the exponential decline
of T cell production with age. Despite the decrease in T cell
production from the thymus, overall T cell counts in the blood
remain approximately constant due to increased peripheral
clonal expansion (1). We therefore make the prediction that
T cell efficacy is not increased by clonal expansion.
Our hypothesis and results add to the understanding of in-
fectious disease and cancer incidence, suggesting in the latter
case that immunosenescence, rather than gradual accumulation
of mutations, serves as the predominant reason for an increase in
cancer incidence with age for many cancers. For future therapies,
including preventative therapies, strengthening the functionality
of the aging immune system (30) appears to be more feasible
than limiting genetic mutations, which raises hope for effective
new treatments.
Methods
Immunological Model. Simplemodels can often be very powerful in explaining
complex phenomena (31, 32). With this in mind, we formulated a minimal
model for disease incidence that does not attempt to explain the data
exhaustively, but rather aims to be as simple as possible for the purposes of
investigating the primary factors and rate-limiting steps.
During an immune response, immunogenic cells will be eliminated, while
also increasing in number through division, such that the number of im-
munogenic cells follows a (biased) random walk. This stochastic birth–death
process has been studied previously (10). The probability for reaching a
population threshold K is given by the following:
bK−1
d −b
dK −bK
, [1]
where b and d are the birth (division) rates and death rates, respectively. The
threshold K is interpreted as the largest number of immunogenic cells that
can be effectively controlled by the immune system, and is thus the IET.
Multiplying by the rate of initiating events r, we arrive at the predicted risk
profile:
R= r   bK−1
d −b
dK −bK
. [2]
We assume that the only factor depending on age is K. The decrease of the
IET with age is supported by experiments in mice showing a decline in
proliferative capacity of activated T cells with age (33, 34). Specifically, we
assume that the IET is proportional to the rate of export of naive T cells from
the thymus. This would be the case if, for example, each T cell progenitor
can only produce a finite number of daughter T cells and respond effectively
to a finite maximum number of immunogenic cells, analogous to the Hay-
flick limit of replicative senescence (35). This gives K =K0   e−α  t, leading to a
predicted risk profile of the form R=A=ðeBe−α  t − 1Þ, where A = r(d − b)/b, B =
K0 log(d/b).
Immunogenic cells are likely to have a higher division rate than normal
cells, but since they are eliminated by the immune system, they will also have
a higher death rate. Under the approximation that the division rate is equal
to the death rate, Eq. 3 reduces to R=A′eα  t, where A′ = r/K0. This consti-
tutes a first-approximation prediction for risk profiles, with just a single
fitting parameter.
When the fitting parameter B is negative, the biological parameters b and
d satisfy b > d. In these rare cases, growth is approximately exponential and
essentially a deterministic process, rather than a rare stochastic event. This
would imply that the size of the threshold plays a small role and that in-
cidence would be close to constant, which is indeed the case. For the ma-
jority of cases, especially the cases that can be fit well, the fitting parameter
B is positive. To obtain a more easily interpreted model for these cases, we
can repackage the parameter B and rewrite the full risk profile as follows:
R=
A
ee−αðt−τÞ − 1
, [3]
where τ = log(B)/α. The parameter τ can now be interpreted as a pivot age,
marking a change in behavior of the risk profile. For ages less than τ, the risk
profile can be approximated as a steep Gompertz function R∼Ae−e−αðt − τÞ ,
while for ages greater than τ, the risk profile can be approximated as a pure
exponential R∼Aeαðt−τÞ. In more biological terms, the pivot age represents
the age when a cancer type transitions from very rare to relatively less rare.
The median pivot age across all cancer types is τ = 49.9 y of age. The immune
system’s response to a given cancer type influences the death rate d and also
the immune exhaustion threshold size K0. In this way, a more competent
immune system would lead to an increase in the pivot age parameter τ.
Up to a shift in age and an overall multiplicative factor, all functions of the
form (6) can be collapsed onto a single universal scaling function given by
the following:
SðxÞ= e− 1
ee−x − 1
, [4]
where x = α(t − τ) and the overall multiplicative factor is chosen such that
S(0) = 1. For the universal scaling function separated by gender, we have
used values of exponent α higher in males than females. Since the available
data on gender-separated TREC decline found in ref. 4 are very noisy (α for
male TRECs is given by 0.08, with 0.05–0.11 95% CI, while α for female TRECs
is given by 0.04, with 0.01–0.07 95% CI), we have arrived at values for α in
males and females based on disease data. The cancer type which fits IM-I
best is “soft tissue including heart.” This cancer has risk rising exponentially
with exponents αM = 0.046 for males and αF = 0.038 for females, which we
use for the universal scaling function. Consistently, the only infectious dis-
ease with gender separation, WNV, rises exponentially with exponents αM =
0.05 for males and αF = 0.041 for females.
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The universal scaling function in Fig. 3 depicts the top 20 best-fitting
cancers as measured by the Akaike information criterion (AIC). Other
choices of measure give similar results (Fig. S10).
The immunological model above can be combined with the PLM to pro-
duce amodel with three fitting parameters. To do so, we alter the assumption
that potentially cancerous cells are produced at a constant rate, r, and assume
instead that they arise from the gradual accumulation of driver mutations.
Using the framework of the PLM (6, 7), the rate of attempts then takes the
form r = r0tγ, corresponding to the waiting time for γ + 1 rare independent
events. This PLIM predicts risk profiles of the following form:
R=
A
eBe−αt − 1
tγ , [5]
where A = r0(d − b)/b, B = K0 log(d/b).
Data Sources. Data sources for incidence rates are chosen based on largest
possible sample sizes.
All cancer incidence data are obtained from Surveillance, Epidemiology,
and End Results Program (SEER) in the United States (11).
Bacterial infection incidence data are obtained from the ABC surveillance
program run by the Centers for Disease Control and Prevention (CDC). This
program studies seven key bacterial diseases in detail (https://www.cdc.gov/
abcs/reports-findings/surv-reports.html).
Incidence data for viral diseases is obtained from studies with the largest
possible sample sizes. WNV disease incidence data are obtained from a
9-y survey covering the United States from 1999 to 2008 (available at https://
www.cdc.gov/mmwr/preview/mmwrhtml/ss5902a1.htm; accessed February 23,
2016). Influenza A incidence data are obtained from a 22-y survey covering
the United States (36).
Tuberculosis prevalence in Cambodia is obtained from ref. 37.
Stem cell counts and division rate estimates are taken from ref. 19.
Statistical Methods. For incidence of infectious diseases and cancers, CIs are
calculated assuming a χ2 distribution. All fitting of incidence curves is per-
formed on log-transformed values.
To calculate the overall ratio of male TRECs to female TRECs, we computed
the ratio of the means and then used a bootstrapping approach to calculate
the SD of that measurement.
To show that cancer risk rises more steeply for males compared with fe-
males, we fit pure exponentials to the incidence curves and recorded the
exponents as Female alpha and Male alpha in Dataset S1. To calculate the
value of P for the statement that risk rises more steeply for WNV in males
compared with females, we used the ANCOVA method.
All of the code for our analysis is available online at https://github.com/
Albluca/ImmuneModelSEER.
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